2018 American Transplant Congress
Impact of Direct Acting Antiviral Agents (DAAs) for Hepatitis C Virus (HCV)-Induced Liver Diseases on Registration and Outcome on Waiting List (WL) for Liver Transplant (LT)
2d-generation DAAs have dramatically improved the management of patients with HCV, including patients with advanced diseases. In France, since 2013, DAA have been largely used,…2018 American Transplant Congress
Impact of Direct Antiviral Therapy for Hepatitis C on Acute Rejection and DSA Formation in Kidney Transplant Recipients
Cleveland Clinic, Cleveland, OH.
Background: Hepatitis C virus infection (HCV) has historically portended a poor outcome after kidney transplantation. With recent advent of direct antiviral agents (DAA), there has…2018 American Transplant Congress
Impact of Direct Acting Antivirals of Hepatitis C Virus Therapy on Tacrolimus Dosing Post-Liver Transplant
Michigan Medicine, Ann Arbor, MI.
Background: Direct acting antivirals (DAA) have transformed hepatitis C virus (HCV) management post-liver transplant (LT). As HCV clears, hepatic metabolism improves, resulting in decreased tacrolimus…2018 American Transplant Congress
Safety and Efficacy of Sofosbuvir-Based Direct-Acting Antiviral Agents in Kidney Transplant Recipients with HCV: A Systematic Review and Meta-Analysis
Background: Outcome data on sofosbuvir (SOF)-based therapy in patients with kidney transplantation (KTx) with hepatitis C virus infection are limited with individual studies having a…2018 American Transplant Congress
Private Insurance is Associated with Reduce Access to HCV Therapy after Liver Transplantation
Effective treatment for hepatitis C virus (HCV) infection has revolutionized post liver transplant (LTx) care. Administration of direct-acting antiviral agents (DAAs) after HCV+ LTx results…2018 American Transplant Congress
Elbasvir-Grazoprevir (Zepatier) is Effective and Safe for the Treatment of Chronic Hepatitis C (HCV) Genotype 1 Virus in the Post Kidney Transplant Patient
Objective: Limited real world data exists regarding the use of direct acting antivirals (DAA) for HCV viremia in renal transplant patients, particularly those with marked…2018 American Transplant Congress
Incidence of Acute Cellular Rejection in Liver Transplant Patients Receiving Direct Acting Antivirals for Hepatitis C Treatment
Direct acting antivirals (DAAs) have been used for the treatment of hepatitis C (HCV) in liver transplant patients since early on after their approval, however…2018 American Transplant Congress
One-Year Outcomes in Patients with Advanced Liver Fibrosis or Compensated Cirrhosis from Chronic Hepatitis C Receiving Kidney Transplant Alone
Background: Hepatitis C (HCV) was difficult to treat post-kidney transplant prior to the direct acting antiviral (DAA) era. As such patients with advanced fibrosis and…2018 American Transplant Congress
Cost Effectiveness of Hepatitis C Positive Donor Kidney Transplantation for Hepatitis C Negative Recipients with Concomitant Direct-Acting Anti-Viral Therapy
Virginia Commonwealth University, Richmond.
Background: The development of direct acting antiviral (DAA) therapy for hepatitis C virus (HCV) could allow for safe and effective treatment following renal transplantation (RT).…2018 American Transplant Congress
Treatment of HCV Infection in Renal Transplant Recipients
Renal Transplant Unit, Instituto de Nefrologia Nephrology, Buenos Aires, Argentina.
HCV infection is associated to chronic hepatitis, cirrhosis, hepatic carcinoma and increased incidence of diabetes. Combination of new antiviral drugs have demonstrated utility in liver…
- « Previous Page
- 1
- …
- 15
- 16
- 17
- 18
- 19
- …
- 28
- Next Page »